Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Nanoparticle delivery of a prodrug-activating bacterial enzyme leads to anti-tumor responses

PROVIDER: PRJNA1090507 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR28411184_1.fastq.gz	Fastqsanger.gz
	SRR28411184_2.fastq.gz	Fastqsanger.gz
	SRR28411185_1.fastq.gz	Fastqsanger.gz
	SRR28411185_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

Identification of YqfB enzyme expressed in colorectal cancer cell line HCT116 using LC-MS/MS proteomics

Project description:Gene-directed enzyme prodrug therapy is an emerging strategy for cancer treatment based on the delivery of a gene that encodes an enzyme that is able to convert a prodrug into a potent cytotoxin exclusively in target cancer cells. The aim of this study is to determine the capability of bacterial amidohydrolases to activate novel prodrugs and the effect such system has on the viability of eukaryotic cancer cells. HCT116 cancer cell line was subjected to LC-MS/MS proteomic analysis to confirm bacterial YqfB amidohydrolase expression at protein level.

2024-01-26 | PXD045918 | Pride

Escherichia coli msbB-deficient mutant extracellular vesicle proteome

Project description:Bacteria actively secrete extracellular vesicles (EVs), spherical nano-sized proteolipids into the extracellular milieu. Bacterial EVs have gained wide interests as non-living complex vaccines or delivery vehicles. However, no studies have used bacterial EVs in treating cancer so far. Our results showed remarkable capability of EVs derived from Escherichia coli W3110 msbB-deficient mutant to effectively induce long-term anti-tumor immune responses that can fully eradicate established tumors without notable adverse effects. This anti-tumor effect was IFN-γ-dependent, and we present a comprehensive proteome of E. coli W3110 msbB-deficient EVs to investigate which vesicular components induce the anti-tumor effects.

2018-11-22 | PXD006912 | Pride

Staphylococcus aureus RN4220 wild-type extracellular vesicle proteome

Project description:Bacteria actively secrete extracellular vesicles (EVs), spherical nano-sized proteolipids into the extracellular milieu. Bacterial EVs have gained wide interests as non-living complex vaccines or delivery vehicles. However, no studies have used bacterial EVs in treating cancer so far. Our results showed remarkable capability of EVs derived from Staphylococcus aureus RN4220 wild-type to effectively induce long-term anti-tumor immune responses that can fully eradicate established tumors without notable adverse effects. This anti-tumor effect was IFN-γ-dependent, and we present a comprehensive proteome of S. aureus RN4220 wild-type EVs to investigate which vesicular components induce the anti-tumor effects.

2018-11-22 | PXD006913 | Pride

Gene therapy using genome-edited human iPS cell-derived neural stem cells overcomes refractory course of invasive glioma stem cells

Project description:Spatiotemporal analyses using brain slice culture and brain clearing demonstrated that human induced pluripotent stem cell-derived neural stem cells (iPSC-NSCs) possess higher tumor-trophic migratory capacity than fetal NSCs, adipose tissue and bone marrow derived mesenchymal stem cells (MSCs). NSCs expressing prodrug converting enzyme fusion gene exhibited strong anti-tumor effect for glioma stem cell in vivo models. The present research concepts may become a platform of cell-based gene therapy for glioma.

2022-09-16 | GSE150470 | GEO

ProCTLA-4 in anti-tumor immunity

Project description:We developed a prodrug of the anti-CTLA4 antibody, named ProCTLA-4. ProCTLA-4 elicits anti-tumor immune responses with reduced toxicity compared to current CTLA4 blockade therapies. Moreover, compared to currently used Probody Therapeutics targeting CTLA-4, ProCTLA-4 offers significant advantages for enhanced efficacy. Thus, our design establishes an alternative paradigm for antibody therapeutics that enables reduction of irAEs while simultaneously increasing therapeutic efficacy.

2025-08-20 | GSE305582 | GEO

Prevention of mammary tumor progression by silencing HoxA1 via intraductal injection of nanoparticle-formulated siRNA

Project description:Silencing HoxA1 in vivo by intraductal delivery of nanoparticle-formulated siRNA reduced mammary tumor incidence by 75% , reduced cell proliferation, and prevented loss of ER and PR expression. 8 week wild type FVB mouse whole mammary gland and 8week to 20 week transgenic FVB C3(1)-SV40Tag mouse whole mammary gland

2013-12-31 | E-GEOD-50813 | biostudies-arrayexpress

Human Breast Tumor-associated Endothelial Cells Favor Interactions with Nanomedicines

Project description:Nanomedicines, designed to improve the effectiveness of cancer treatment, have not met anticipated outcomes owing to suboptimal delivery efficiency to tumors. While the enhanced permeability and retention (EPR) effect has been explored, recent research challenges the predominant passive accumulation theory. This study explores the mechanisms governing nanoparticle entry into tumors by comparing human breast tumor-associated endothelial cells (HBTECs) and healthy human mammary macrovascular endothelial cells (HMMECs). Our results demonstrate that HBTECs exhibit higher nanoparticle uptake, involving three major endocytic pathways. Gene expression analysis reveals the upregulation of transport-related genes, especially motor protein genes, in tumor-associated endothelial cells. These insights highlight the need for comprehensive investigations into nanoparticle transport mechanisms and associated factors within the tumor microenvironment, essential for advancing drug delivery and therapeutic outcomes.

2024-09-01 | GSE253737 | GEO

Prevention of mammary tumor progression by silencing HoxA1 via intraductal injection of nanoparticle-formulated siRNA

2013-12-31 | GSE50813 | GEO

Analyses of mIRNA transcript level following exposure to triptolide

Project description:Analyses of mirna transcript levels following exposure to the drug triptolide in vitro and prodrug minnelide in xenograft pancreatic tumor mouse models. Response of pancreatic adenocarcinoma cell lines to minelide in vitro and exposure to its prodrug triptolide in SCID mouse tumors derived from the same cell lines.

2013-11-12 | E-GEOD-46188 | biostudies-arrayexpress

Lipid nanoparticles deliver DNA-encoded biologics and induce potent protective immunity

Project description:Lipid nanoparticles (LNPs) for mRNA delivery have advanced significantly, but LNP-mediated DNA delivery still faces clinical challenges. This study compared various LNP formulations for delivering DNA-encoded biologics, assessing their expression efficacy and the protective immunity generated by LNP-encapsulated DNA in different models. The LNP formulation used in Moderna’s Spikevax mRNA vaccine (LNP-M) demonstrated a stable nanoparticle structure, high expression efficiency, and low toxicity. Notably, a DNA vaccine encoding the spike protein, delivered via LNP-M, induced stronger antigen-specific antibody and T cell immune responses compared to electroporation. Single-cell RNA sequencing (scRNA-seq) analysis revealed that the LNP-M/pSpike vaccine enhanced CD80 activation signaling in CD8+ T cells, NK cells, macrophages, and DCs, while reducing the immunosuppressive signals. The enrichment of TCR and BCR by LNP-M/pSpike suggested an increase in immune response specificity and diversity. Additionally, LNP-M effectively delivered DNA-encoded antigens, such as mouse PD-L1 and p53R172H, or monoclonal antibodies targeting mouse PD-1 and human p53R282W. This approach inhibited tumor growth or metastasis in several mouse models. The long-term anti-tumor effects of LNP-M-delivered anti-p53R282W antibody relied on memory CD8+ T cell responses and enhanced MHC-I signaling from APCs to CD8+ T cells. These results highlight LNP-M as a promising and effective platform for delivering DNA-based vaccines and cancer immunotherapies.

2025-01-22 | GSE272803 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data